Mitiperstat Drug Asset Due Diligence Report 2026

This Mitiperstat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Mitiperstat can convert its Small molecule drug profile and MPO biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Mitiperstat (query alias: mitiperstat)
Modality / target	Small molecule drug; MPO; MPO inhibitors
Highest global status	Phase 2
Originator	AstraZeneca PLC
Active developers	AstraZeneca AB

The MCP disease footprint includes Cardiomyopathy, Dilated, Heart Failure, Systolic, Ischemic cardiomyopathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05492877	Phase 2	Completed	381	To Evaluate the Effect of Mitiperstat (AZD4831) as Compared to Placebo on the Time to First COPD Composite Exacerbation (CompEx) Event in Patients With Moderate to Severe COPD.
EUCTR2022-003797-23-DE	Phase 2	Not Recruiting	112	Change in log NTproBNP levels from baseline to week 12 (mitiperstat vs. placebo)
NCT05638737	Phase 2	Completed	112	Relative to Baseline Alanine Aminotransferase (ALT)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non‐Cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis

Phase 2; n=112; evaluation: Negative. Reported fields: ALT = 7.5 % ; ALT = 7.5 %

A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 2; n=381; evaluation: not stated. Reported fields: To Evaluate the Effect of Mitiperstat (AZD4831) as Compared to Placebo on the Time to First COPD Composite Exacerbation (CompEx) Event in Patients With Moderate to Severe COPD. = 125 Participants ; To Evaluate the Effect of Mitiperstat (AZD4831) as Compared to Placebo on the Time to First COPD Composite Exacerbation (CompEx) Event in Patients With Moderate to Severe COPD. = 125 Participants ; To Evaluate the Effect of Mitiperstat (AZD4831) as Compared to Placebo on the Time to First COPD Composite Exacerbation (CompEx) Event in Patients With Moderate to Severe COPD.: Hazard Ratio (HR) = 1.071(90% CI, 0.869 - 1.320), P-Value = 0.599

A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Phase 2/3; n=711; evaluation: not stated. Reported fields: Kansas City Cardiomyopathy Questionnaire -Total Symptom Score(Least Squares Mean) = 11.62 Points (95% Confidence Interval, 9.54 - 13.71); Kansas City Cardiomyopathy Questionnaire -Total Symptom Score(Least Squares Mean) = 9.81 Points (95% Confidence Interval, 7.73 - 11.90); Kansas City Cardiomyopathy Questionnaire -Total Symptom Score(Least Squares Mean): Mean Difference (Final Values) = -0.92(95% CI, -3.86 to 2.02), P-Value = 0.537; Mean Difference (Final Values) = -1.81(95% CI, -4.71 to 1.09), P-Value = 0.221

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Mitiperstat addresses Cardiomyopathy, Dilated, Heart Failure, Systolic, Ischemic cardiomyopathy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: MPO records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2024-08-08	Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments	Phase 1	Financial terms not disclosed
2024-03-28	ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome	Phase 2	Financial terms not disclosed
2018-09-05	Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “MPO inhibitors for use in medicine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO